about
Mild cognitive impairment and depressive symptoms in elderly patients with diabetes: prevalence, risk factors, and comorbiditySerum levels of inflammatory markers in depressed elderly patients with diabetes and mild cognitive impairment.Serum Soluble Adhesion Molecules and Markers of Systemic Inflammation in Elderly Diabetic Patients with Mild Cognitive Impairment and Depressive SymptomsC-Reactive Protein, Advanced Glycation End Products, and Their Receptor in Type 2 Diabetic, Elderly Patients with Mild Cognitive Impairment.Adiponectin, leptin and IL-1 β in elderly diabetic patients with mild cognitive impairment.Expression of IL-7 receptor in human peripheral regulatory T cellsPlasma levels of thrombomodulin, plasminogen activator inhibitor-1 and fibrinogen in elderly, diabetic patients with depressive symptomsPneumococcal and seasonal influenza vaccination among elderly patients with diabetes.Risk factors associated with irreversible airway obstruction in nonsmoking adult patients with severe asthma.ZAP70 expression in regulatory T cells in allergic rhinitis: effect of immunotherapy.[Serum sICAM-1 in patients suffering from allergic rhinitis treated with fexofenadine or fluticasone].Predictors of poor glycaemic control in type 2 diabetic elderly patients with depressive syndrome.[Occurrence of atopy in asthmatic children]Orally exhaled nitric oxide in patients with seasonal allergic rhinitis during natural pollen seasonUse of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitissICAM-1 and TNF-α in asthma and rhinitis: relationship with the presence of atopyHistamine type 2 receptor expression on peripheral blood regulatory lymphocytes in patients with allergic rhinitis treated with specific immunotherapy[The importance of diet in the prevention of adverse reactions to vitamin K-dependent anticoagulants]
P50
Q34561934-9DD980BA-5914-47A9-8479-40196AFCF4E6Q35203024-774BEACB-1BAE-4211-82D7-69A3E98E9F32Q35808049-CE39A45D-C2CD-4965-A2A5-3E502B40E258Q36221514-36B1C0EE-EEBD-40C6-815B-BCCFD3EFF910Q36686081-7A18194C-6DAD-4C62-8210-0AB6A1439D07Q36983965-4D52232C-754C-44C5-ADC5-0382EB84B248Q37239432-0DC84AA2-A203-4022-A81B-D63F22D80034Q40328748-B09F12A5-5E71-43EB-B00B-764E1E4C67CFQ41711140-DFD8729C-A1A4-43B4-9C41-DA6694AFA613Q46828422-72ACBBC5-2029-40D0-8718-6416BF124A66Q46836588-34BFA1ED-3B77-4C9A-8CA1-5F4FD766E7B9Q48306866-14A75A59-5A9B-411F-B983-78C985416F58Q80381482-1C41205F-E73A-40FC-9F85-129ACE92ED86Q83574201-6136373D-C0B6-4CFE-9D0B-D56CE84A7CCAQ84462862-9AE93741-4B8E-4296-B057-294F38F9ED3FQ84755880-9793F67A-391F-43E2-A2CC-A57BF62CB424Q88186638-BDF275EB-8048-468C-967C-C193FF0F289FQ90606174-12CC90AD-36DA-4D68-B7CD-FEBB6284CDDD
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Małgorzata Górska-Ciebiada
@en
Małgorzata Górska-Ciebiada
@nl
type
label
Małgorzata Górska-Ciebiada
@en
Małgorzata Górska-Ciebiada
@nl
prefLabel
Małgorzata Górska-Ciebiada
@en
Małgorzata Górska-Ciebiada
@nl
P31
P496
0000-0002-0065-4376